ResearcherGerman Cancer Research CenterNo recent work listed
Sebastian Schölch
Matched on ORCID iD 0000-0003-0012-3177; OpenAlex author ID A5085323535. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 21
2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 2 papers
Papers 5
- GAS2L1 Is a Potential Biomarker of Circulating Tumor Cells in Pancreatic Cancer. Last author DOI 10.3390/cancers12123774↗
- Characterization of Stem-like Circulating Tumor Cells in Pancreatic Cancer. Last author DOI 10.3390/diagnostics10050305↗
- Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer. Co-author DOI 10.1186/s12885-017-3225-5↗
- Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection. Co-author DOI 10.18632/oncotarget.20315↗
- Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.2651↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christoph Reißfelder · 4 shared papers, 2017–2020 · strength 0.36
- Paper Characterization of Stem-like Circulating Tumor Cells in Pancreatic Cancer. DOI 10.3390/diagnostics10050305↗
- Paper GAS2L1 Is a Potential Biomarker of Circulating Tumor Cells in Pancreatic Cancer. DOI 10.3390/cancers12123774↗
- Paper Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection. DOI 10.18632/oncotarget.20315↗
- Cui Yang · 3 shared papers, 2017–2020 · strength 0.31
- Paper Characterization of Stem-like Circulating Tumor Cells in Pancreatic Cancer. DOI 10.3390/diagnostics10050305↗
- Paper GAS2L1 Is a Potential Biomarker of Circulating Tumor Cells in Pancreatic Cancer. DOI 10.3390/cancers12123774↗
- Paper Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection. DOI 10.18632/oncotarget.20315↗
- Lei Zhu · 2 shared papers, 2020 · strength 0.24
- Balázs Győrffy · 2 shared papers, 2020 · strength 0.24
- Nuh N. Rahbari · 3 shared papers, 2014–2017 · strength 0.16
- Paper Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection. DOI 10.18632/oncotarget.20315↗
- Paper Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer. DOI 10.1186/s12885-017-3225-5↗
- Paper Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. DOI 10.18632/oncotarget.2651↗
- Christoph Kahlert · 3 shared papers, 2014–2017 · strength 0.16
- Paper Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection. DOI 10.18632/oncotarget.20315↗
- Paper Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer. DOI 10.1186/s12885-017-3225-5↗
- Paper Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. DOI 10.18632/oncotarget.2651↗
- Jürgen Weitz · 2 shared papers, 2017 · strength 0.12
- Sonja Loges · 1 shared paper, 2020 · strength 0.11
- Mathieu Pecqueux · 2 shared papers, 2014–2017 · strength 0.09
- Georg Feldmann · 1 shared paper, 2017 · strength 0.06
- Bianca T. Hofmann · 1 shared paper, 2017 · strength 0.06
- Tristan Lerbs · 1 shared paper, 2017 · strength 0.06
- Savita Bisht · 1 shared paper, 2017 · strength 0.06
- Thilo Welsch · 1 shared paper, 2017 · strength 0.06
- Martin A. Schneider · 1 shared paper, 2014 · strength 0.03
- Massimiliano Mazzone · 1 shared paper, 2014 · strength 0.03
- Thomas Schmidt · 1 shared paper, 2014 · strength 0.03
- Moritz Koch · 1 shared paper, 2014 · strength 0.03
- Niels Halama · 1 shared paper, 2014 · strength 0.03
- Alexis B. Ulrich · 1 shared paper, 2014 · strength 0.03
- Christian P. Pilarsky · 1 shared paper, 2014 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.